One possible explanation of our findings may reside in the molecular target of trastuzumab which is the extracellular domain of HER-2 [41] which may be cleaved and shed from the surface of breast cancer cells generating a truncated 95-kd intramembrane protein [42]. Here, ERBB2 is linked to breast cancer.